European vaccine makers want EU exemptions that would protect them if there are problems with new Covid-19 vaccines, and low interest rates have helped US homebuilder stocks surge to record highs. Plus, the FT’s James Fontanella-Khan explains why Ant Group chose to list its potentially record setting IPO outside the US. Covid-19 vaccine makers lobby EU for legal protectionhttps://www.ft.com/content/12f7da5b-92c8-4050-bcea-e726b75eef4d?Low rates help propel US homebuilder stocks to record highshttps://www.ft.com/content/9b54ab06-2d57-44a1-85c2-47c114589c22Ant Group reveals $2.6bn profit as it files for blockbuster IPOhttps://www.ft.com/content/b5f6fed2-2dcf-48dc-9097-a49bff5532dc Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.